Aktien Sensor

Swedish Orphan Biovitrum AB (SOBI) has secured European Union marketing authorization for Tryngolza (olezarsen), a gene-silencing therapy for familial chylomicronemia syndrome (FCS), following a positive opinion from the CHMP and robust data from th…

Swedish Orphan Biovitrum AB, a leading biopharmaceutical company, is poised to shape the future of the industry with its strong market presence and promising growth prospects.

Sobi has successfully completed the issuance of class C shares, securing its long-term commitments and positioning the company for potential future growth.

Swedish Orphan Biovitrum AB reported a strong Q2 performance, with a 25.55% revenue increase to $639.2 million and a 7-fold increase in earnings per share, despite a slight dip in stock price.

Swedish Orphan Biovitrum AB’s Q2 2025 report shows a 13-22% revenue increase, driven by the launch of Altuvoct and growth in haematology revenue.

Swedish Orphan Biovitrum AB is expected to report strong earnings on July 16, driven by a significant increase in revenue and earnings per share, as well as FDA approval for its treatment Gamifant.

Swedish Orphan Biovitrum AB has secured approval for its treatment Gamifant to tackle Macrophage Activation Syndrome in Still’s disease, a major milestone for the company in rare disease treatment.

Swedish Orphan Biovitrum AB (SOBI) reported a 3% increase in Q1 2025 revenue, driven by a 13% surge in haematology segment sales.

SOBI is set to release its Q1 2025 earnings on April 29, with Berenberg reaffirming its buy recommendation and lowering its price target to 360 kronor.

SOBI’s Annual Report highlights the company’s efforts to develop rare disease therapies, but raises questions about its commitment to sustainability and innovation, leaving shareholders and stakeholders uncertain about its future direction.